spacer
home > pmps > spring 2017 > security breach
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Security Breach

Approximately 40% of all pharmaceutical products available in the US are manufactured outside of the country. It is thought that 80% of the active ingredients in drugs are made and delivered from all over the world, and these must meet the country-specific regulatory requirements of the locations in which they are going to be sold. This highlights the complexity of the industry’s supply chain.

Like many high-value commodities, pharmaceuticals are attractive to criminals – whether they are online hackers or opportunistic individuals who hijack a truck and remove its goods – with no concern whether they are life-saving drugs, prescription medication or lifestyle products.

Negating threats means thoroughly assessing your entire distribution network to determine penetration points. This can include screening vendors to ensure that they have the proper cybersecurity measures in place; scrutinising physical vulnerabilities along the route where goods can be tampered with; and identifying countries and regions with high risks for disruptions to business continuity that can potentially impact your ability to get products from point A to B.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Steve Ward serves as Vice President for the Global Intellectual Property Protection division at Pinkerton, a global provider of corporate risk management services including security consulting, investigations, executive protection, employment screening, protective intelligence and more.
spacer
Steve Ward
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

When space is tight

Existing packaging lines can be retrofitted for serialization tasks, achieving a maximum of space savings and process reliability: if required, the system comes with an integrated checkweigher and tamper-evident labeler.  
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

Clinical Trial Supply Nordics 2018

19-20 June 2018, Copenhagen, Denmark

Building on last year’s success, our CTS team have conducted extensive research to ensure the 2018 event programme covers all the essentials in clinical supply. In the current climate, every pharma and biotech company are trying to reduce unwanted costs, and enhance operational efficiency. To avoid costly setbacks, an innovative and effective strategy needs to be implemented!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement